Article Text

Download PDFPDF

4CPS-063 Erenumab versus galcanezumab, effectiveness in real-life experience
  1. M Rodriguez Goicoechea,
  2. B Sanchez Rodriguez,
  3. M Sanchez Valera,
  4. F Verdejo Reche,
  5. I Alferez Garcia
  1. Hospital Universitario Torrecárdenas, Pharmacy, Almeria, Spain


Background and importance Erenumab and galcanezumab have been the first prophylaxis option in migraine since the arrival of calcitonine gene-related peptide inhibitors (CGRPi). In clinical trials, their effectivity has been set after 12 weeks of treatment.

Aim and objectives Evaluate the efficacy difference between both treatments using real-world data.

Material and methods A retrospective, observational study was performed from January 2020 to July 2021.Patients with more than 12 weeks of treatment were analysed. Evaluation of response on patients’ interviews with neurologists and pharmacists, extracting data from clinical history. Comparison with the other drug and the clinical trial results.

Results Of 95 patients with migraine on treatment with CGRPi, 77 were included in our study. They were 67 women, with an average of 50.6 years. 29 patients received galcanezumab, and 48 erenumab. Most patients started treatment with 70 mg.

After 12 weeks of treatment, clinical trials obtained a reduction in monthly migraine days (MMD) of ≥50% and ≥75% in 58.3% and 20.8% of patients receiving erenumab and 72.4% and 37.8% in those receiving galcanezumab. Their clinical trials showed an MMD reduction of ≥50% and ≥75% in 39.9% and 17.0% with erenumab and 62.3% and 38.8% with galcanezumab.

Comparing both treatments with their clinical trials, erenumab gets better results in the real world, although both treatments get similar results as in clinical trials with a reduction of 75%. Confronted with both treatments, galcanezumab has better results in real life, reducing MMD in ≥50% (72.4% vs 58.3%).

Conclusion and relevance Erenumab and galcanezumab seem to achieve better results in real patients, but galcanezumab appears better than erenumab, although both treatments are better than their clinical trials. Facing them, galcanezumab seems to achieve a better response, so further studies are required to check this observation out.

These new treatments can improve a patient’s quality of life, so their use should be reviewed and follow up should be collaborative between neurologists and pharmacists to see the real effect of this medication.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.